Basic information Pharmacological effects Biological Activity Indications Dosage Side effects Other clinical research Safety Related Supplier
Ruxolitinib Structure

Ruxolitinib

Chemical Properties

Melting point 84-89°C
Density  1.40
storage temp.  -20°
solubility  Soluble in DMSO (up to 28 mg/ml) or in Ethanol (up to 15 mg/ml with warming).
form  White powder.
pka 11.63±0.50(Predicted)
color  White
Stability Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
InChI InChI=1/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/s3
InChIKey HFNKQEVNSGCOJV-UJHUVDBMNA-N
SMILES [C@@H](C1CCCC1)(N1N=CC(C2N=CN=C3NC=CC=23)=C1)CC#N |&1:0,r|
CAS DataBase Reference 941678-49-5
Ruxolitinib is the first oral medication approved by the US Food and Drug Administration (FDA) for the treatment of myelofibrosis. It is a small-molecule inhibitor of the tyrosine kinase (namely, JAK1 and JAK2) and is suitable for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia Vera myelofibrosis and post essential thrombocythemia myelofibrosis.

Safety Information

HS Code  29335990
Hazardous Substances Data 941678-49-5(Hazardous Substances Data)

Usage And Synthesis

Ruxolitinib Supplier

Ruxolitinib manufacturers